Skip to main content
 
  • Engineering any genome, at any site, in any way

  • Focused on the advancement of new applications for CRISPR-based technologies

  • Exploring the vast potential of CRISPR-Cas technology across therapeutics, agricultural biotech, biological research and industrial biotech

News

Caribou Biosciences Announces FDA Clearance of its IND for CB-010, an Off-the-shelf Allogeneic Anti-CD19 CAR-T Cell Therapy

September 8, 2020
First allogeneic CAR-T cell therapy with PD-1 deleted by CRISPR genome editing cleared for Phase 1 clinical trials Upon initiation of the ANTLER Phase 1 clinical trial, CB-010 will be Caribou’s first clinical-stage product candidate...

Caribou Biosciences Appoints Cherry Thomas, MD as Senior Vice President of Clinical Development

May 11, 2020
BERKELEY, Calif.--Caribou Biosciences, Inc., a leading CRISPR genome editing company, today announced the appointment of Cherry Thomas, MD, as Senior Vice President of Clinical Development. In this newly created position, Dr. Thomas will...

Our Approach

Caribou Biosciences is a pioneer in the revolutionary field of CRISPR-Cas genome editing.  Our proprietary technology puts us at the forefront of the development of new medical therapies and bio-based products which offer profound benefits to both human health and society as a whole. 

Our singular focus is on the advancement of new applications for CRISPR-Cas gene editing that will help bring the tremendous promise this technology holds for patients and consumers to reality.

Learn More...